Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

8%

Beneficial ownership of this reported class.

Shares

3,940,052 shares

Shares beneficially owned as disclosed.

Event date

31 Dec 2024

Date tied to the ownership event or amendment.

Accepted by SEC

14 Feb 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
PBYI
Shares outstanding
49,250,650 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13G/A
Accepted by SEC
14 Feb 2025, 12:14:08 UTC
Event date
31 Dec 2024
Prior SEC filing
14 Nov 2024
Source filing
View source filing

Key filing fact

ACORN BIOVENTURES, L.P. disclosed 8% ownership in PUMA BIOTECHNOLOGY, INC. Common Stock, $0.0001 par value per share (PBYI) on 31 Dec 2024.

Key facts

  • ACORN BIOVENTURES, L.P. filed SCHEDULE 13G/A for PUMA BIOTECHNOLOGY, INC. Common Stock, $0.0001 par value per share (PBYI).
  • Disclosed ownership: 8%.
  • Date of event: 31 Dec 2024.

Change

  • Previous schedule filing date: 14 Nov 2024.
  • Current filing was accepted on 14 Feb 2025, 12:14.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (5)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
ACORN BIOVENTURES, L.P. 3.3% 1,654,823 0 1,654,823 Anders Hove Manager
ACORN BIOVENTURES 2, L.P. 4.7% 2,285,229 0 2,285,229 Anders Hove Manager
ACORN CAPITAL ADVISORS GP, LLC 3.3% 1,654,823 0 1,654,823 Anders Hove Manager
Anders Hove 8% 3,940,052 0 3,940,052 Anders Hove Manager
Acorn Capital Advisors GP 2, LLC 4.7% 285,229 0 2,285,229 Anders Hove Manager
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .